Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)

LESSONS LEARNED. Everolimus does not have sufficient activity to justify its use as single agent in metastatic melanoma. Patients treated with 10 mg per day dose were most likely to require dose reductions. Everolimus appeared to reduce the numbers of regulatory T cells in approximately half of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Vera Aguilera, Jesus, Rao, Ravi D., Allred, Jacob B., Suman, Vera J., Windschitl, Harold E., Kaur, Judith S., Maples, William J., Lowe, Val J., Creagan, Edward T., Erickson, Lori A., Markovic, Svetomir
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156180/
https://ncbi.nlm.nih.gov/pubmed/29666297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados